Results 51 to 60 of about 14,652 (127)

Empagliflozin attenuates ventricular fibrillation postmyocardial infarction associated with reduced transforming growth factor-1/Smad3 signaling and miR-181a expression

Journal of International Medical Research
Objective To determine whether empagliflozin reduces ventricular fibrillation and myocardial fibrosis after myocardial infarction via the transforming growth factor-β1/Smad3/miR-181a pathway.
Jingsong Shen, Min Huang, Zixu Ye, Yuling Jing, Ziyang Yuan, Zeming Xiang, Miao Ding, Tao Li, Qiang Ye   +8 more
doaj   +1 more source

Letter to the Editor: Indication-Specific Cost-Effectiveness of Empagliflozin Versus Dapagliflozin: Implications for Clinical and Policy Decision-Making. [PDF]

Hosp Pharm
Belančić A.
europepmc   +1 more source

Long-term Empagliflozin Use in Chronic Syndrome of Inappropriate Antidiuresis Due to Traumatic Subarachnoid Hemorrhage. [PDF]

JCEM Case Rep
Kyriakidou A, Shekhda KM, Waung JA, Tzoulis P.   +3 more
europepmc   +1 more source

Efficacy of empagliflozin in patients with metabolic dysfunction-associated steatotic liver disease with or without diabetes: a systematic review and meta-analysis of randomized controlled trials. [PDF]

Front Med (Lausanne)
AlHussaini KI.
europepmc   +1 more source

Enhancing evidence-based care using trial emulation in electronic health records: real-world effects of empagliflozin in people with type 2 diabetes. [PDF]

BMJ Open Diabetes Res Care
Ryan DK, Keogh RH, Williamson E, Lumbers RT, Diaz-Ordaz K, Shah AD, Bidulka P.   +6 more
europepmc   +1 more source

Empagliflozin and its impact on hepatic and metabolic outcomes in patients with type 2 diabetes and NAFLD: a systematic review and meta-analysis. [PDF]

Diabetol Metab Syndr
Hamzah KA, Shweliya MA, Kurmasha YH, Ahmed MJ, Habib A, Kamel AII, Rashid Z, Shimal AA, Moghazy M, Fahem F, Al Aboud MY, Elgazzar A, Mahgoub AMA, Al-Shammari AS.   +13 more
europepmc   +1 more source

Effect of empagliflozin on urinary albumin excretion and hypoxic biomarkers in early diabetic kidney disease: A randomised double-blind, placebo-controlled trial. [PDF]

Diabetes Obes Metab
Makino H, Kasahara M, Takashima R, Kasama S, Ozu N, Park H, Chen Q, Tsuruya K, Tochiya M, Omura-Ohata Y, Tamanaha T, Noguchi M, Aiba T, Yoshihara F, Hosoda K.   +14 more
europepmc   +1 more source

Timing-dependent anti-inflammatory effects of empagliflozin in monocyte-derived macrophages from post-myocardial infarct patients with type 2 diabetes. [PDF]

Cardiovasc Diabetol
Cliff CL, Shah MU, Ward JK, Inghels M, Lee K, Squires PE, Hills CE.   +6 more
europepmc   +1 more source

Fecal microbiome predicts treatment response after the initiation of semaglutide or empagliflozin uptake. [PDF]

Sci Rep
Klemets A, Reppo I, Krigul KL, Volke V, Aasmets O, Org E.   +5 more
europepmc   +1 more source

Empagliflozin in paediatric heart failure: model-based optimisation of a pharmacokinetic bridging study. [PDF]

Front Med (Lausanne)
Lava SAG, Di Deo A, D'Agate S, Della Pasqua O.   +3 more
europepmc   +1 more source